JAMES BAUGHMAN: Open Payments
NPI 1932861580 · TYLER, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,777 in 154 payments from 12 companies in 2025. Trend: 2023 $3,231 · 2024 $925 · 2025 $3,777
Food & beverage: $3,705Education: $71
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 23 | $597 |
| Teva Pharmaceuticals USA, Inc. | 18 | $567 |
| Vanda Pharmaceuticals Inc. | 28 | $559 |
| Otsuka America Pharmaceutical, Inc. | 15 | $364 |
| Neurocrine BioSciences, Inc. | 14 | $341 |
| Janssen Pharmaceuticals, Inc | 9 | $340 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $323 |
| Lundbeck LLC | 18 | $201 |
| E.R. Squibb & Sons, L.L.C. | 10 | $194 |
| Axsome Therapeutics, Inc. | 5 | $183 |
Products named: FANAPT, REXULTI, UZEDY, INGREZZA, CAPLYTA, ARISTADA, LYBALVI, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
